Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study - Scorecard - MDSpire
Advertisement
Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study
Clinical Scorecard: Effectiveness and Safety Comparison of Adjuvant Trastuzumab with Pertuzumab versus Trastuzumab Emtansine in HER2-Positive Breast Cancer Patients with Residual Disease Following Neoadjuvant Therapy: A Retrospective Analysis
At a Glance
Category
Detail
Condition
HER2-positive breast cancer
Key Mechanisms
Adjuvant trastuzumab plus pertuzumab (HP) versus trastuzumab emtansine (T-DM1)
Target Population
Patients with HER2-positive breast cancer and residual invasive disease after neoadjuvant therapy
Care Setting
Retrospective observational study
Key Highlights
Remove unsupported conclusion about real-world evidence.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Remove unsupported claims about monitoring for adverse events.
Risks
Remove unsupported claims about increased risk of hospitalization.
Patient & Prescribing Data
Revise to reflect findings without editorial interpretation.
Clinical Best Practices
Revise to ensure practices are based on study results.
